Glycosaminoglycans may help postpone peritoneal failure in long-term continuous ambulatory peritoneal dialysis (CAPD)
This article was originally published in Clinica
Administering glycosaminoglycans to patients on long-term continuous ambulatory peritoneal dialysis (CAPD) may help maintain the efficiency of the treatment, say Italian researchers in the Lancet (September 16th). Previous observations had shown that glycosaminoglycans have a protective effect on peritoneal structure and function in diabetic and other experimental rats.
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.